Lawton Instrumental Activities of Daily Living Scale
The Lawton Instrumental Activities of Daily Living (IADL) scale assesses the more complex activities of daily living necessary for living in the community, such as shopping, cooking and managing finances. These skills are usually lost before other activities of daily living functions are, such as bathing, dressing and eating.
ECOG Performance Status
The Eastern Cooperative Oncology Group (ECOG) performance status is a scale used to assess how a patient’s disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
Brief Fatigue Inventory
The Brief Fatigue Inventory is a simple yet sensitive tool that allows the severity and impact of cancer-related fatigue to be assessed.
Supportive care
No publications this month related to supportive care in myeloma
Diagnostic tests and prognostic indicators
Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Giles SL et al. Clin Radiol. 2015 Mar 19. pii: S0009-9260(15)00074-4. doi: 10.1016/j.crad.2015.02.013. [Epub ahead of print]. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Franssen LE et al. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.48.…
Related conditions
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Bochtler T et al. J Clin Oncol. 2015 Mar 16. pii: JCO.2014.57.4947. [Epub ahead of print]. Extracorporeal Membrane Oxygenation as Bridge-to-Decision in Acute Heart Failure due to Systemic Light-Chain Amyloidosis. Mancio Silva J et al. Am J Case Rep. 2015 Mar 24;15:174-81.…
Emerging treatments
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Seggewiss-Bernhardt R et al. Cancer. 2015 Mar 24. doi: 10.1002/cncr.29339. [Epub ahead of print]. O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies. Herait…